SLC2A4 and diabetes mellitus: One of the most interesting therapeutic applications of RA is its use in the treatment of diabetes, through an effect mediated by reducing the expression of the enzyme phosphoenolpyruvate carboxykinase and increasing the expression of the glucose transporter GLUT4 [45].